Ovarian/Peritoneal Cancer
Phase II Randomized Double-Blind Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND #79,610) [GOG 0214]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab, in Women with Newly-Diagnosed, Previously-Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer [GOG 0218]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab, in Women with Newly-Diagnosed, Previously-Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer [GOG 0218 CTSU]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Phase II Trial of AZD6244 (NSC #741078, IND #33382) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary [GOG 0239] Temporarily closed to approval
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
Advanced, Persistent or Recurrent Disease
A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube,or Primary Peritoneal Carcinoma [GOG 0170K] Temporarily closed to accrual
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of AMG 706 (IND #79.697) in Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Amgen Study #10070747) [GOG 170L] Temporarily closed to accrual
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma [GOG 0170M]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of Abraxane in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Abraxis BioScience, Inc. Study # ABX-005) [GOG 0126R]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase II Evaluation of Docetaxel plus Trabectedin (IND #101018) with Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer [GOG 0186F] Temporarily closed to accrual
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing Twelve Monthly Cycles of Single Agent Paclitaxel or Xytotax (CT-2103) (IND #70177) versus No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy [GOG 0212]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel alone or in Combination with Bevacizumab ( NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer. NCI-Supplied Agents: Bevacizumab [GOG 0213]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN
Ovarian Stromal Tumor
Phase II Study of Paclitaxel for Ovarian Stromal Tumors Second-Line Therapy [GOG 0187]
Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN